NCT02681055View on ClinicalTrials.gov

Open-Label Study To Evaluate MN-001 on HDL & Triglyceride in NASH & NAFLD Subjects

PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

May 30, 2018

Study Completion Date

October 1, 2019

Conditions
Non-alcoholic SteatohepatitisHypertriglyceridemiaNon-alcoholic Fatty Liver DiseaseHypercholesterolemia
Interventions
DRUG

MN-001

MN-001 is a novel, orally bioavailable small molecule compound which demonstrates anti-inflammatory activity

Trial Locations (3)

92037

Scripps Research, La Jolla

92118

Southern California Research Center, Coronado

98104

Harborview Medical Center, Seattle

Sponsors

Lead Sponsor

MediciNova
All Listed Sponsors
lead

MediciNova

INDUSTRY

NCT02681055 - Open-Label Study To Evaluate MN-001 on HDL & Triglyceride in NASH & NAFLD Subjects | Biotech Hunter | Biotech Hunter